Description

Poly(D,L-lactide-co-glycolide)

Poly(D,L-lactide-co-glycolide) (PLGA) is a pharmaceutical-grade, biodegradable copolymer used extensively in controlled-release drug delivery systems, long-acting injectables, implantable devices, and biomedical scaffolds. Its tunable composition allows precise control over degradation rates and drug release kinetics, making it one of the most established polymers in regulated pharmaceutical and biomedical applications. PDLLA

• Is a pharmaceutical-grade biodegradable copolymer
• Offers compositionally adjustable lactide:glycolide ratios to control degradation rate
• Supports microspheres, injectable depots, implantable drug reservoirs, and tissue engineering scaffolds
• Is fully biocompatible, hydrolytically degrading into lactic and glycolic acids

Poly(D,L-lactide-co-glycolide) is synthesized via ring-opening polymerization of D,L-lactide and glycolide monomers. By adjusting the lactide-to-glycolide ratio (typically ranging from 50:50 to 85:15), formulators can fine-tune the polymer’s crystallinity, hydrophilicity, and degradation profile, ranging from weeks to several months.

In pharmaceutical controlled-release formulations, PLGA is widely used to produce microspheres, long-acting injectables, subcutaneous implants, and drug-eluting devices that deliver small molecules, peptides, proteins, and vaccines over extended periods. Its degradation into lactic and glycolic acids, both metabolized through normal physiological pathways, supports complete in vivo resorption.

In biomedical engineering, PLGA serves as a core material for resorbable sutures, orthopedic implants, regenerative scaffolds, wound healing matrices, and advanced tissue engineering constructs, where both short- and long-term resorption profiles are required.

Pharmaceutical developers and biomedical manufacturers seeking to purchase Poly(D,L-lactide-co-glycolide) benefit from CarboMer’s precise molecular weight control, tight compositional specifications, validated manufacturing processes, and full regulatory support for global development programs.

The polymer is supplied in moisture-protected, tamper-evident packaging to ensure long-term stability throughout storage and shipping. Minimum order quantities (MOQ), lead times, and complete regulatory documentation are available to support both early-stage development and commercial-scale production.

Each batch is rigorously tested for lactide:glycolide ratio, molecular weight distribution, residual monomers, residual solvents, heavy metals, and microbial safety, ensuring consistency and full regulatory compliance.

As with all CarboMer biomaterials, Poly(D,L-lactide-co-glycolide) is supported by end-to-end technical consultation, formulation development assistance, and regulatory expertise to accelerate drug delivery programs and global regulatory submissions.